We continue to have a strong commitment to medical research and the advancement of treatments for all conditions of eye diseases. If you or someone you know is interested in more information about our clinical research trials in Ophthalmology, please call 909-558-2233 or email the research coordinators Norlisha Borntrager, Rebecca Pereyra and Wilson Mojica.

Current Clinical Trials

RETINA

  1. DRCR Genes: Genes in Diabetic Retinopathy Project. The goal of this project is to create a repository of at least 5000 participant’s blood to define factors that confer risk for development and progression of Diabetic Retinopathy and other retinal diseases and response to therapeutic intervention. Must be enrolled in a DRCR study to participate. PI: Dr. David Sierpina
  2. DRCR AF- A Randomized Clinical Trial Evaluating Fenofibrate for Prevention of Diabetic Retinopathy Worsening. This randomized trial will evaluate the effect of fenofibrate compared with placebo for prevention of diabetic retinopathy (DR) worsening or center-involved diabetic macular edema (CI-DME) with vision loss through 4 years of follow-up in participants with mild to moderately severe non-proliferative DR (NPDR) and no CI-DME at baseline.  PI: Dr. David Sierpina
  3. DRCR AM- Randomized trial comparing immediate versus deferred surgery for symptomatic Epiretinal Membrane. PI: Dr. Kakarla Chalam
  4. Samsara-Sing- A prospective multicenter clinical study of the implantable miniature telescope in patients with central vision Impairment associated with end-stage age-related macular degeneration (AMD) PI: Dr. Michael Rauser
  5. DRCR- AN- A phase 2 evaluation of Tonabersat for Diabetic Macular Edema. PI: Dr. David Sierpina

CORNEA

  1. Neurotrophic Keratitis: A multi-Center, randomized double-masked, vehicle- controlled parallel group, study to evaluate the safety and efficacy of CSB-001 Ophthalmic solution 0.1% in Stage 2 and 3 Neurotrophic Keratitis subjects. PI: Dr. John Affeldt
  2. KPI-012- A study to evaluate the safety and efficacy of KPI-012 ophthalmic solution in participants with persistent corneal epithelial defect (PCED). PI: Dr. John Affeldt
  3. RGN-NK-302- A phase 3 multi-center randomized parallel double-masked, placebo controlled clinical study to assess the safety and efficacy of 0.1% RGN-259 ophthalmic solution for the treatment of Neurotrophic Keratopathy (SEER-2) PI: Dr. John Affeldt

PEDIATRIC STUDIES

 

  1. PEDIG ATS22: Randomized Trial to Evaluate Sequential vs Simultaneous Spectacles plus Patching for Amblyopia in Children 3 to <13.  PI: Dr. Timothy Winter
  2. IXT-7- Randomized trial of full-time occlusion therapy for intermittent exotropia in children. PI: Dr. Timothy Winter